When it comes to manufacturing quality controls (QCs), choosing the right raw material is essential. Controls need to be accurate, reliable, consistent, and closely mimic real patient samples. But with factors like supply consistency and sustainability, cost, stability, and performance to be considered, how do you decide whether a native or synthetic biological raw material is best? This article explores the advantages, disadvantages, and provides expert insights on selecting the best approach for quality control development.

 

Understanding Native and Synthetic Raw Materials

Native Biological Raw Materials

Native raw materials are biological substances derived from humans or extracted from human-based materials such as native antigen extracts, tissues, cells, blood, serum, plasma, and other bodily fluids. These materials undergo minimal processing to preserve their functional integrity, making them highly relevant in research, therapeutic applications, and diagnostic testing.

Examples of Native Materials:

  • Defibrinated human disease state plasma processed to resemble serum.
  • Natively derived biofluids (e.g., serum, plasma) formulated with purified native analytes like proteins, enzymes, or antibodies to achieve required concentrations.

Synthetic Biological Raw Materials

Synthetic raw materials are engineered biological substances designed to mimic or enhance the functionality of native biological counterparts. They are produced using molecular biology techniques and can offer advantages in terms of stability, scalability, and purity.

Examples of Synthetic Materials:

  • Synthetic plasma or serum matrices made from buffers, polymers, or animal-derived components.
  • Recombinant proteins (e.g., antigens, enzymes, synthetic antibodies) produced via genetic engineering.
  • Modified biomolecules incorporating chemical cross-linking to achieve desired performance or enhance stability.

 

Evaluating Native vs. Synthetic Raw Materials: A Comparative Analysis

To support informed decision-making, the following provides a comparative analysis outlining the advantages and disadvantages associated with native and synthetic raw materials:

Feature Native Raw Materials Synthetic Raw Materials
Biological Relevance High, often more commutable with patient samples May differ from native samples, depending on complexity
Functionality Maybe superior for complex multimeric proteins, cofactors, and post-translational modifications May lack certain native functionalities, but can be optimised
Lot-to-Lot Consistency Natural variability due to biological differences High consistency across batches
Scalability Limited, depends on biological sourcing More easily scalable for high production volumes
Risk of Contamination Potential for human pathogens and biological contaminants Lower contamination risk, free from human pathogens
Ethical Considerations Ethical considerations when sourcing from human donors, particularly high-titre materials from patients No human donor concerns
Stability & Purity Variable stability and risk of degradation if not stored properly Generally, more stable and higher purity
Cost & Availability Can be cost-effective but may be limited by supply Expensive to develop but offers greater availability
Development Time Readily available providing access to suitable donors is sustainable Longer initial development and scale-up time

 

Expert Insights: Native Materials and Their Unique Advantages

One of the most critical factors when selecting raw materials for quality controls is ensuring that they mirror actual patient samples in their response to assay system changes. Experts note that native materials often provide better commutability, meaning they exhibit similar shifts and biases to patient samples when instrument performance, reagents, or calibrators change.

One of our industry experts shared an example where a human-derived cholesterol control detected an assay issue, while an animal-derived control failed to flag the problem. This highlights a key benefit of using native materials—ensuring that quality control samples respond to system variations in the same way as real patient samples.

However, native materials present several challenges, including biological variability, limited scalability, and potential contamination risks. Some complex proteins, such as haemoglobin tetramers and various growth factors, require precise folding, complex subunit assembly and/or post-translational processing, which can be difficult to replicate outside of the natural host organism.  While synthetic biotechnology techniques continue to improve, some proteins are still best sourced through their native sources.

 

Synthetic Materials: Achieving Consistency and Scalability

Synthetic and recombinant materials provide greater consistency and scalability, making them attractive alternatives when native materials are costly or difficult to obtain. Recombinant proteins and synthetic matrices eliminate pathogen risks and offer batch-to-batch consistency.

However, some synthetic raw materials lack key post-translational modifications (PTMs) or require complex folding that native systems inherently achieve. Certain recombinant antibodies, for instance, may not perfectly replicate the native structure due to difficulties in assembling heavy and light chains with correct disulfide bonds. Mammalian expression systems can mitigate some of these issues but add to production costs and complexity.

 

Making the Right Choice: Practical Considerations

Functionality vs. Feasibility

  • If functional integrity and biological relevance are the top priorities, native materials may be preferable.
  • If lot-to-lot consistency and large-scale production are essential, synthetic materials should be considered.

Cost and Supply Constraints

  • Native materials may be cost-effective when high-titre sources are available but can be limited in supply.
  • Synthetic materials often require high initial investment but ensure consistent availability in the long run.

Testing in Feasibility Studies

A practical approach maybe to evaluate both native and synthetic options during feasibility studies. As one industry expert advises:

“I believe there is still a perceived superiority of native materials in quality control development. However, if synthetic options provide cost or availability advantages, I will include them in my feasibility studies and assess their performance. Sometimes, synthetic options can outperform native materials in cost effectiveness, availability, and even performance!”

 

Conclusion: Striking a Balance Between Native and Synthetic

The decision between native vs. synthetic raw materials depends on a careful balance of biological relevance, scalability, and cost. While native materials often provide superior functionality and commutability, synthetic materials offer greater consistency, scalability, and reduced contamination risks.

The debate between native and synthetic raw materials will likely continue, but by understanding their strengths and limitations, QC manufacturers can make informed decisions. Whether you’re using native or synthetic biological raw materials, the right choice depends on your specific needs and the parameter being tested.

Understanding the Challenges of Quality Control Manufacturers

IVD manufacturers face a range of challenges when sourcing biological raw materials. Each manufacturer has unique requirements based on the specific assays and controls they produce, making the selection process highly nuanced. The need for consistent, scalable, and high-quality raw materials is critical, yet these attributes can be difficult to guarantee due to the inherent variability of biological sources.

Lot-to-lot consistency ensures that Quality Control (QC) manufacturers can maintain consistent analyte target concentrations in their products, facilitating smooth validation processes and ensuring regulatory compliance. This article explores the key considerations for QC manufacturers in achieving lot-to-lot consistency when utilising bulk biological raw materials.

 

The Importance of Lot-to-Lot Consistency

For a QC manufacturer, obtaining multiple samples across multiple lots of raw material is critical for qualification and validation purposes. The primary concerns include:

  • Consistent Analyte Values: QC manufacturers must ensure that each lot of material maintains expected analyte concentrations, enabling laboratory personnel to perform accurate patient testing. Variability in analyte values can result in regulatory challenges and usability issues.
  • Reliable Availability: Uninterrupted supply of biological raw materials ensures that QC manufacturers can meet demand and avoid backorders due to material rejection.
  • Scalability: As QC manufacturers expand their market share, the ability to scale raw material supply without compromising quality is crucial.

 

Requirements for Raw Materials

Lot-to-Lot Consistency

Ensuring lot-to-lot consistency is essential to maintaining QC product performance. Variability in raw material specifications such as titre, analyte concentration, and pH can lead to significant manufacturing disruptions. If a batch of raw material falls outside of predefined specifications, it can result in product rejection, requiring costly deviations and re-validations.

Raw material suppliers must implement validated manufacturing processes to guarantee uniformity. By maintaining strict quality controls, suppliers help QC manufacturers achieve seamless transitions when onboarding new lots of control materials.

Reliable Supply Chain

A dependable supply chain is vital for ensuring that QC manufacturers receive raw materials in a timely and stable manner. Delays in raw material shipments can cause backorders, disrupting production and impacting end users. Global shortages of certain biological materials have, in the past, forced manufacturers to implement deviations or retrospective validations—costly challenges that highlight the importance of a supplier with robust inventory management and production planning.

Scalability and Growth

As QC manufacturers expand their market share, their need for increased raw material volumes grows. A supplier’s ability to scale production in tandem with demand is an important factor. Without the capacity to meet growing requirements, manufacturers may face interruptions or be forced to qualify alternative materials mid-production—an expensive and time-consuming process. Scalability ensures manufacturers can confidently plan for future needs without compromising product integrity.

Certificate of Analysis and Stability Testing

A comprehensive Certificate of Analysis (CoA) that includes testing of critical parameters is an essential requirement for QC manufacturers. This ensures that each lot meets established specifications and reduces the risk of unexpected performance issues.

Biological raw materials must maintain stability over time to ensure consistent performance. Real-time stability testing assesses parameters such as titre, activity, concentration, and microbial contamination over a defined shelf-life. If materials degrade over time or accumulate contaminants, they may no longer be suitable for QC applications, leading to batch rejections, customer complaints, backorders, patient safety issues, and increased costs.

Sampling and Retain Program

QC manufacturers benefit from suppliers who implement robust sampling and retain programs. These programs serve multiple purposes:

  • Design and development validation: While raw materials are not typically subject to the same stringent design controls as medical devices, they must undergo validation to support product claims.
  • Validation Processes: At least three lots of raw materials are typically required for design and process validation, making access to multiple retained lots a significant advantage.
  • Troubleshooting: Retained samples enable QC manufacturers to investigate and resolve potential issues efficiently.

 

Technical Considerations for Quality Control Manufacturers

Certain technical challenges can complicate the use of biological raw materials in QC applications. Understanding these issues helps manufacturers make informed decisions.

Protease Activity and Analyte Stability

Protease activity can degrade sensitive analytes in many QC materials. It may originate from microbial contamination and may persist despite efforts to eradicate, neutralize or filter out the microbes. Proteases may also arise from endogenous sources from delayed or improper processing leading to lysis of cells prior to the separation of the plasma/serum component.  Once active, these enzymes can reduce analyte stability and compromise test accuracy.

Albumin Conformation and Stability

Denatured or partially denatured albumin is a lesser-known but significant problem in serum-based products. The three-dimensional structure of albumin plays a crucial role in maintaining analyte stability. Exposure to heat, pH shifts, or denaturing compounds like urea, guanidine or organic solvents, can alter this structure, causing analytes to bind unpredictably. Partially denatured albumin may bind analytes such as hormones, peptides, and enzymes, causing analyte loss and inconsistencies in QC products. Even slight misfolding can lead to assay discrepancies across different instrument platforms, making consistent albumin conformation a critical consideration.

Co-Morbidities in Disease State Materials

Disease state materials often contain a complex mix of cross-reactive antibodies, which can lead to unexpected interferences in QC manufacturing. Ensuring that disease state specimens meet specific inclusion criteria is essential to maintaining product reliability.

Inactivation Processes and Their Trade-Offs

Some inactivation processes, such as heat treatments used to eliminate proteases, can have unintended consequences. While effective at reducing protease activity, these treatments may also denature critical proteins, reducing marker titres and affecting overall performance. Understanding the impact of inactivation techniques on raw material integrity is key to selecting suitable specimens.

 

The Value of Validated Processes

Robust processes that preserve biological raw material integrity are essential for ensuring consistent, reliable performance of QC manufacturers controls and ensuring commutability across different instrument platforms. Selecting the right raw material from the outset minimises the need for costly reformulations and process deviations.

At Logical Biological, we are committed to working closely with our customers to define customised specifications that deliver the performance and consistency their applications demand. Our vision is to provide Insightful Solutions that Make a Difference—ultimately contributing to Improved Health Outcomes.

To turn this vision into reality, we have made significant investments over the past year, in new, expanded state-of-the-art laboratory space, broadening our R&D capabilities, and scaling up our processes and operations. These advancements strengthen our ability to support Quality Control and IVD Assay manufacturers with a sustainable, high-quality supply of critical biological raw materials—ensuring they can meet both operational and regulatory requirements with confidence.

We are proud to announce the appointment of Stephane Argivier as our new Chief Executive Officer, effective from 1st September 2024. Stephane Argivier will lead the next stage in the company’s expansion and succeeds Dr. James Steggles, the company’s founder, who announces he will remain Chair of the Board.

 

The announcement follows recent company successes in which Logical Biological received prestigious accolades, including securing the 149th spot in the “FT 1000: Europe’s Fastest Growing Companies” listing and a King’s Award for International Trade, recognising 5 years of impressive growth for Logical Biological.

 

Stephane Argivier, former CEO at MIP Discovery, recently renamed as Tozaro, and previously Managing Director at SCIPAC, now part of BBI Solutions; became Non-Executive Director and member of the Board at Logical Biological in 2021.

 

Stephane Argivier has a successful track record with over 25 years’ experience in growing critical reagent businesses for applications in ‘in-vitro’ diagnostics and Life Science tools. As Managing Director of SCIPAC, he transformed the company’s business model and offering, to achieve broad market adoption of customer centric products. SCIPAC was sold to the multinational BBI Solutions in 2010.

 

Stephane has also played a key role in shaping the Logical Biological strategy to date, which has underpinned its stellar growth.  As a successful Life Science business leader with depth of expertise in clinical biospecimens and the affinity diagnostic reagents market, Stephane is ideally suited to lead a smooth transition, scale the business and lead its ambitious expansion plans.

 

Biospecimen and manufactured bioreagents are critical for R&D, validation, manufacture and QC of diagnostic assays, and yet quality, sustainability and technical support can be a challenge to meet the ever-increasing standards required in ‘in vitro diagnostics’. Logical Biological aims to deliver an unmatched level of quality, expertise and technical understanding of customer applications to address these.

 

Dr. James Steggles, Chair of Logical Biological, said: “We are delighted that Stephane has agreed to become our new CEO. His leadership and expertise will drive Logical Biological forward in its mission to deliver a sustainable supply of critical material solutions to accelerate our customers diagnostic and therapeutic advancements’’

 

Stephane Argivier

Stephane Argivier, incoming Chief Executive, said: “I joined Logical Biological as CEO because I could see the great potential in the company, knowing the value of deep expertise, quality and exceptional customer service to deliver critical and complex bioreagent solutions to the IVD market. In my 4 years with the business as a Board Director, I have been impressed by the quality of our people, know-how and the strength of our client relationships, which provide strong foundations on which to build in the years ahead. I believe we have an exciting future in front of us to expand the business and deliver value for our customers and shareholders.’’

We are proud to announce that Logical Biological has been honoured with the King’s Award for Enterprise. This prestigious award recognises Logical Biological’s excellence in International Trade for Outstanding Short-Term Growth in overseas sales over the last three years (2020-2022), which amounted to a more than one hundred and seventy per cent increase in international revenues during the period. This growth was achieved organically, amidst the challenging circumstances of the COVID-19 pandemic and is a mark of the company’s excellent reputation and unwavering commitment to providing high-quality biological samples to its diagnostic and therapeutic customers.

 

The King’s Awards for Enterprise, previously known as The Queen’s Awards for Enterprise, were renamed last year to reflect His Majesty The King’s desire to continue the legacy of HM Queen Elizabeth II’s by recognising outstanding UK businesses. The Award programme, now in its 58th year, is the most prestigious business award in the country. The awards celebrate the success of exciting and innovative businesses which are leading the way in one of four categories: Innovation, International Trade, Sustainable Development and Promoting Opportunity (through social mobility).

 

“We are delighted to receive the King’s Award for International Trade, which affirms our role as a leader in the global biospecimens market,” expressed Dr James Steggles, Managing Director of Logical Biological. “This award is a testament to the tireless efforts of our team and the trust our customers place in us as their supplier of choice for high-quality biospecimens. Our commitment to excellence not only propels our growth but also significantly furthers our mission to contribute to a healthier world.”

Kings Award For Enterprise International Trade Emblem

Over the three-year period, Logical Biological worked with a record number of customers, including many of the top 10 global leading companies in In Vitro Diagnostics (IVD) test manufacturing. It shipped products to twenty-four countries (including the USA, Germany, South Korea, Ireland, and Australia), and continues to expand its reach globally. The success of Logical Biological on a global scale can be attributed to its comprehensive range of biological samples and its commitment to quality, reliability, customer service, and responsiveness. The company’s deep understanding of the international scientific community’s needs, coupled with its focus on a customer-centric approach and strict quality control protocols, ensure superior product quality and customer satisfaction.

 

Lowri Cope, Commercial Director at Logical Biological, added, “We are immensely proud to be recognized for our outstanding growth in international trade. Our strong relationships within the global In Vitro Diagnostics (IVD) community form the foundation of our success. We are excited to continue this trajectory, expanding our partnerships and enhancing our role in diagnostics and therapeutic research and development.”

 

This recognition is not just an award but a reflection of Logical Biological’s dedication to impacting the global healthcare landscape positively.

We’re excited to share a milestone in our journey at Logical Biological. Our relentless dedication to customer centricity and unwavering commitment to quality has led to us securing 149th spot in the prestigious “FT 1000: Europe’s Fastest Growing Companies” listing, a recognition that fills us with immense pride and joy.

 

The “FT 1000” list, created in collaboration with Statista, shines a spotlight on the European companies that have shown extraordinary growth. The ranking is determined by analysing the compound annual growth rate (CAGR) in revenue from 2019 to 2022. In a list that is dominated by IT, Software, Construction and Energy/ Utility companies, Logical Biological is proud to be leading the way for science.

 

Our Managing Director, Dr James Steggles, reflects on this achievement with gratitude, attributing it to the hard work of our team and the trust our customers place in us. “This recognition validates our team’s dedication and the close relationships we’ve built with our partners who share our vision of creating a healthier world. It’s their trust in us as a provider of high-quality biospecimens that has propelled our growth.”

FT 1000: Europe's Fastest Growing Companies

Our position in the list is not just a number—it’s a narrative of our dedication to delivering excellence. Our expansive array of biological samples, combined with our focus on responsiveness, reliability, and quality, illustrates our commitment to the scientific community. We strive to understand and meet their needs ensuring that our products and services exceed expectations and maintain the highest quality standards.

 

Lowri Cope, Commercial Director, echoes this sentiment, expressing enthusiasm for our future endeavours. “Being acknowledged as one of Europe’s fastest-growing companies is a milestone that fuels our ambition. We look forward to building on this success and forging new partnerships in the advancement of scientific research and healthcare.”

 

As we celebrate this achievement, we’re not just looking back at our successes—we’re looking forward to the opportunities that lie ahead. Our vision is clear. Join us as we continue to forge ahead, solidifying our role as your trusted partner for biospecimens.

Logical Biological is dedicated to fostering sustainability, operating with ethics and integrity, and striving to reduce our environmental footprint. In-fact one of our 6 company values set down as the founding principles of our company is “We do we what we can to reduce our environmental impact.” This principle is deeply embedded in our company culture, influencing our daily activities, and guiding our efforts towards creating a more sustainable future for everyone.

 

Our Carbon Offsetting Journey

Early in 2023 we made a firm commitment to carbon offset all our incoming and outgoing freight and set about measuring our carbon tonnage. Throughout the year this goal expanded, and we increased our commitment to include our carbon tonnage (Scopes 1 & 2) for the following;

  • Freight for all shipments
  • Business Travel
  • Staff Commuting
  • Office Lab equipment (electrical usage etc)
  • Office and Lab Space lighting etc
  • Dry Ice

We opted to work with Native, a US based public benefit and certified B corporation, to ensure our carbon offsets achieve our company’s sustainability goals, which are based on the 17 UN Sustainable Development Goals (SDGs).

We are proud to announce that we have offset our carbon impact and are carbon neutral for the above activities in 2023.

 

Sustainability Projects we are Supporting

We have offset our 2023 carbon footprint by purchasing verified emissions reductions’ credits (VER’s) to support 2 projects for the next 20 years;

  1. Brazil Pastureland Regeneration project

The Brazil Pastureland Regeneration with Native Palm Silvopasture Project works with smallholder farms in Brazil to plant native Macaúba palms in degraded pasturelands. This work will create a silvopasture system that sequesters carbon in the soil, provides shade for grazing livestock, and supports biodiversity, while providing a responsibly grown source of palm. It will remove >900,000 tCO2e over 20 years and have a substantial impact on the community by providing additional income for 100+ farms and jobs for over 300 people.

  1. Mozambique Clean Water project

The Mozambique Clean Drinking Water Project, led by the non-profit Village Water, rehabilitates, installs, and maintains borehole water infrastructure to provide communities with safe, clean drinking water. The project also;

  • builds capacity and offers training at the local level around managing water sources into the future.
  • reduces the risk of waterborne illnesses and the need to boil water for purification, which saves over 95,000 tonnes of firewood annually and reduces CO2 emissions.
  • improves sanitation and hygiene practices in the communities.
  • allows women and girls to spend more time on other activities previously dedicated to collecting water and firewood.

As a result of this project to date, over 36,000 people have access to clean drinking water, and over 98 million litres of drinking water are supplied annually.

 

2023 Sustainable Development Goal Achievements

Reducing inequalities was also part of our 2023 sustainability goals. In February 2023, we sought your insights through our customer satisfaction survey. In response to each completed survey, we made donations to PATH, an international organization dedicated to advancing health equity worldwide. Your participation not only aided our sustainability endeavors but also supported a specific Sustainable Development Goal. We are grateful for your valuable contribution to this vital cause.

Sustainability achievements 2023

Sustainability Programs in the Local Community

We are active members of the local community where we are based, Discovery Park. Annually, we plant Christmas Trees on-site, fostering a green initiative. Additionally, we’ve launched an on-site program for the collection and recycling of printer toner cartridges in Feb 2023.

Christmas Trees growing
Last year’s Christmas Trees

We reuse packaging materials including expanded polystyrene (EPS) boxes, dry ice, and cool packs. Over the last 4 years we have re-used 41% of our EPS boxes for our outgoing shipments.

Logical Biological supports volunteer days and we have an annual volunteer day. In March 2023 we volunteered our time to the Kent Wildlife Trust and spent the day at Sandwich and Pegwell Bay, litter picking and clearing sea-buckthorn which dominates the dunes above the bay. To read more please see our blog.

 

Our Sustainability Credentials

In April 2023 we were awarded a Bronze EcoVadis Medal. EcoVadis measures the quality of a company’s sustainability management system and will be planting a tree on our behalf. Our objective is to consistently improve our performance to attain a higher rating in the 2024 assessment.

EcoVadis Bronze 2023

2024 Sustainability Plan

Our 2024 Sustainability Plan is an extension of our achievements from 2023 and we will continue to review our progress, reinforcing our dedication to environmental stewardship and sustainable business practices. Concentrating on key areas— Environment, Labour and Human Rights, and Ethics — we not only aim to enhance our EcoVadis score significantly, but we are also steadfast in our goal to achieve Carbon Neutrality in 2024 by once again minimising and offsetting all carbon emissions.

Logical Biological is committed to do what we can to reduce our environmental impact and improve our local environment. With this core value in mind some of our team recently enjoyed a blustery day in Sandwich and Pegwell Bay National Nature Reserve volunteering for the Kent Wildlife Trust.

 

Covering 615-hectares (1,520-acres), Sandwich and Pegwell Bay is the Kent Wildlife Trusts largest site and is important for breeding, migrating, and wintering birds all year round. It has rich feeding grounds which are a vital stop for migrating birds, some of which cover thousands of miles and come all the way from places like Canada, Russia, and Africa. The area is also home to many internationally important rare plants and animals, such as lizard orchids and sand lizards.

 

Caption: Sea-buckthorn dominate the dunes above Pegwell bay

 

Sea-buckthorn, as we discovered, is a spiny, thicket-forming shrub that grows well in the sand dunes. In-fact it grows so well that it has taken over too much of the reserve and needed cutting back and managing. That is where our team of volunteers came in! Our team spent the day cutting back the shrub and litter picking the cleared area, making it ready for sand lizard to bask in the summer sun and highland cattle to graze.

Caption: Logical Biologicals team of volunteers

 

With the ideal ratio of shrub to dunes being 25:75%, there’s still a way to go, but we definitely made an impact and hope that we played a part in ensuring the vast biodiversity of the area.

Caption: Rubbish and wayward golf balls collected (there’s an adjacent championship links golf course!)

 

In the four years since it was founded, Logical Biological has established itself as a go-to company for diagnostic test developers, requiring healthy and diseased human biological material such as serum, plasma, swabs, and saliva, directly from donor centres and blood banks around the world.

 

Founder and managing director, James Steggles, set up the business after being persuaded by his family and friends to go it alone and put his years of industry experience to work.

 

With the need to operate from Containment Level 2 laboratory space, James identified the life science park: Discovery Park in the southeast of the UK as the home for his start-up company, Logical Biological.

 

Speaking from his office in Building 500, James said: “Discovery Park offered the space and the all-important containment facilities, and a welcoming approach that made it easy for us to choose to move here.

James Steggles, Founder and Managing Director, Logical Biological

James Steggles, Founder and Managing Director, Logical Biological

 

“Since establishing the company at Discovery Park we’ve grown quickly and already moved to bigger offices and labs twice, with another move onsite on the horizon.”

 

The company’s expertise has helped it establish a global network of partners to help source the human biological material needed by companies involved in the development of disease diagnosis testing.

 

Logical Biological’s aspiration is to be the company of choice for test developers to partner with their 12-strong team. A further three people are expected to join by the end of the year, maintaining it as one of the UK’s fastest growing companies.

 

James, who has a PhD in Biochemistry and years of experience in the industry, felt that there was an opportunity to establish a business that offered integrity, reliability, and quality assurance.

 

“The development of high-quality tests, whether for allergies, auto-immune diseases, cancer, cardiology or infectious diseases, require reliable information gathered from high-quality human material. My experience while working in the industry was that the supply-chain too often failed. I knew that with the right attention to detail, we could do much better,” added James.

 

His confidence has been well-founded. The company now provides human biomaterial to many globally recognised names and often with multiple projects for each ongoing at any one time. Logical Biological’s approach and expertise is being put to good use by test developers involved in a wide range of clinical areas.

 

James added: “Covid-19 shone a light on the value of diagnostic tests and how they can support clinicians across many fields, which has stimulated demand for the materials we are perfectly placed to source and supply.

 

“Repeat business, referrals from existing customers and to potential new ones, has driven our growth. Seeing our work, which is at the start of the development of new tests, come to fruition with the tests being launched into the market, gives all of the team huge satisfaction, and drives us to be even better.”

 

Logical Biological has benefited from the talent pool that exists in Kent, and specifically in the Discovery Park area.

 

“The majority of the CVs we receive from potential team members inevitably mention Pfizer which demonstrates the quality of the skills on offer, and the local universities are delivering science graduates to the area.

 

“We’ve also benefitted from the community of like-minded companies here with shared values, with relationships nurtured by the team on site, and we have developed a strong partnership with at least one other firm at Discovery Park.”

 

Logical Biological’s offices, with its testing and write-up space, put the team in amongst a community of high-growth companies, many of whom have started and flourished at Discovery Park.

 

James concluded: “Being among business owners and scientists who are open to collaborate here means that Discovery Park is a great environment in which to grow.

 

“I am delighted about how great the last four years have turned out. Our success has been built on doing things right through integrity and reliability and an extreme commitment to our customers.”

 

The team has also benefitted from the work-life balance offered by Discovery Park and living in Kent. James frequently commutes by train from Whitstable to Ramsgate and then cycles to work through Pegwell Bay nature reserve, with the sea air getting the day off to a great start.

 

 

Logical Biological were delighted to exhibit for the first time at MEDICA, in Dusseldorf, Germany from 14 – 17 November 2022.

MEDICA – Leading International Trade Fair

MEDICA 2022 Infographic

MEDICA is one of the largest international events for the IVD Diagnostic industry and Logical Biological was one of over 5,000 exhibitors from over 70 countries . Logical Biological was pleased to see that visitor numbers were up from 2021 to more than 81,000 visitors, a significant increase from the 46,000 visitors that attended in 2021. In fact, MEDICA felt almost back to its pre-Covid self with the share of international visitors totalling 75 percent. European countries topped the visitor numbers, followed by South Korea and the USA. India and North African countries were also represented in large numbers. Many visitors noted that after the long pandemic break, they were happy to be able to talk to exhibitors again.

Logical Biological at MEDICA 2022

For Logical Biological, this was the first time exhibiting at MEDICA. Exhibiting gave us the opportunity to increase awareness within the industry of who Logical Biological are and how we can support and empower IVD manufacturers to develop high performance assays and associated calibrator and control material.

Thanks to some bold back-lit graphics we were a noticeable presence in the UK Gambica area of Hall 1, which enabled us to have many conversations with passing visitors, who we look forward to building working relationships with. Our team of three enjoyed over 30 pre-arranged meetings with customers and suppliers, and many more spontaneous ones. Better still, thanks to the support of Gambica we were able to have 2 meetings simultaneously by utilising the shared meeting area that Gambica offers.

MEDICA is always good way to get an overview of the market, to network and to see what the other companies are doing and where the trends are, this year was no exception. We look forward to attending more trade shows this year and further building the relationships we started at MEDICA.

 

Logical Biological Products

Logical Biological specialises in provision of human biospecimens, such as serum, plasma, swabs and saliva, all of which are essential components used in IVD tests, their development, calibration and quality control. 

Date of the next MEDICA in Düsseldorf: 13 –16 November 2023

Logical Biological is delighted to announce the appointment of Stephane Argivier as Non-Executive Director and Board member. Stephane has been involved in IVD and Life Science for the past 23 years, during most of which he has held leadership and executive positions, and built a successful track record of delivering fast and sustained growth with entities ranging from start-ups to multinationals.

Stephane is currently CEO and Board member of MIP Diagnostics, a rapidly growing company with a unique technology expanding the scope of affinity reagent applications & functionalities. Stephane was previously Managing Director at SCIPAC Ltd, a multi-business awards winning company, where he led a successful divestment of the company to the BBI Group on behalf of its shareholders. Stephane stayed with the organisation in various Executive roles for a further 9 years to enable a successful integration to what became BBI Solutions and to set-up a number of new business units, several of which have now reached a significant size. Stephane holds a Masters degree in Business and a degree in Applied Biology.

The appointment comes at a time when Logical Biological has established a strong market position as an ethical, quality focused and reliable source of best-in-industry human biological materials and is now preparing for the next stage of its journey. Dr James Steggles, Managing Director at Logical Biological said, “I am very pleased to welcome Stephane Argivier to the board of Logical Biological. Stephane’s experience in critical IVD reagents, especially within the clinical specimen market, will be extremely valuable as we continue to expand our business operations. We are delighted that Stephane will be joining our board and we look forward to working with him as we continue to build scale and success at Logical Biological”.

Stephane Argivier commented, “I am delighted to be joining Logical Biological at this pivotal time in its business cycle. I am truly impressed with the progress the company has made over the past few years and excited about its future.”